A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose-Escalation, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects
Latest Information Update: 27 Oct 2013
At a glance
- Drugs Ivacaftor (Primary) ; Lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 27 Oct 2013 New trial record